Abstract
The authors compared the efficacy of three different doses (18.75, 37.5, and 75 MU per parotid gland) of botulinum toxin A (BTX-A; Dysport, Ipsen Pharma, Germany) injections vs vehicle in patients with sialorrhea (n = 32) using a single-center, prospective, double-blind, placebo-controlled dose-finding study. The primary endpoint was achieved with 75 MU BTX-A without treatment-related adverse events, suggesting BTX-A is a safe and effective treatment for patients with sialorrhea.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Botulinum Toxins, Type A / therapeutic use*
-
Disease Progression
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Female
-
Humans
-
Injections
-
Male
-
Motor Neuron Disease / complications
-
Neuromuscular Agents / therapeutic use
-
Parkinson Disease / complications
-
Parotid Gland / drug effects
-
Prospective Studies
-
Sialorrhea / drug therapy*
-
Sialorrhea / etiology
-
Treatment Outcome
Substances
-
Neuromuscular Agents
-
Botulinum Toxins, Type A